PremiumThe FlyUnited Therapeutics price target lowered to $420 from $430 at Leerink United Therapeutics price target lowered to $346 from $354 at Morgan Stanley Strong Buy Rating for United Therapeutics Driven by Robust Growth and Promising Pipeline PremiumThe FlyMorning Movers: TJX and Lowe’s gain following fourth quarter results United Therapeutics reports Q4 EPS $6.19, consensus $6.27 UTHR Upcoming Earnings Report: What to Expect? PremiumThe FlyUnited Therapeutics announces FDA clearance of UKidney NDA United Therapeutics to Present at J.P. Morgan Conference Trump Trade: New administration to invest $20B to build data centers 
